Somatuline ( DrugBank: - )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
67多発性嚢胞腎2
298遺伝性膵炎1

67. 多発性嚢胞腎


臨床試験数 : 221 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-005017-37-NL
(EUCTR)
30/05/201221/05/2012To investigate the effect of Lanreotide on renal function decline in ADPKD patientsA randomised, controlled clinical trial assessing the efficacy ofLanreotide to halt disease progression in ADPKD - The DIPAK 1 Study First, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measuredby change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotidemodifies progression of the liver phenotype in the subset of ADPKD patients with moderate to severe polycystic liverdisease as measured by change in liver volume.
MedDRA version: 14.1;Level: LLT;Classification code 10023433;Term: Kidney polycystic;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Somatuline Autogel
Product Name: Lanreotide
Product Code: BIM 23014
INN or Proposed INN: Lanreotide
Other descriptive name: LANREOTIDE ACETATE
DIPAK ConsortiumNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands
2EUCTR2009-017849-57-NL
(EUCTR)
24/03/201113/01/2010Somatostatin analogues as a volume reducing treatment of polycystic livers - SOLVESomatostatin analogues as a volume reducing treatment of polycystic livers - SOLVE Polycystic liver disease, due to isolated polycystic liver disease or polycystic kidney disease.
MedDRA version: 12.1;Level: LLT;Classification code 10048834;Term: Polycystic liver disease
MedDRA version: 12.1;Level: PT;Classification code 10036045;Term: Polycystic kidney
MedDRA version: 12.1;Classification code 10036046;Term: Polycystic kidney, autosomal dominant
MedDRA version: 12.1;Classification code 10036048;Term: Polycystic kidney, unspecified type
Product Name: Sandostatin LAR
Product Code: unknown
Product Name: Somatuline Autosolution
Product Code: unknown
Radboud University Nijmegen Medical CentreNULLNot RecruitingFemale: yes
Male: yes
50Phase 4Netherlands

298. 遺伝性膵炎


臨床試験数 : 95 薬物数 : 148 - (DrugBank : 51) / 標的遺伝子数 : 53 - 標的パスウェイ数 : 142
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-016082-29-BE
(EUCTR)
10/03/201025/11/2009Role of Lanreotide in the Management of Paraduodenal Pancreatitis - LPPRole of Lanreotide in the Management of Paraduodenal Pancreatitis - LPP Paraduodenal pancreatitis
MedDRA version: 12.1;Level: LLT;Classification code 10009093;Term: Chronic pancreatitis
Trade Name: Somatuline Autogel 90 mg
Other descriptive name: LANREOTIDE ACETATE
Erasme hospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Belgium